Infliximab ELISA

Enzyme immunoassay for the quantitative determination of free Infliximab (Remicade®, Remsima®) in serum and plasma.

The solid phase (MTP) is coated by the target molecule, in this case TNF-alpha.

Reference: IG-AA101

Barcode: 8682754930028

Legal Status: CE-Mark

Intended Use: This kit has been developed for the measurement of drug levels in research, diagnostic and biosimilar uses. It is suitable for Therapeutical Drug Monitoring (TDM) purposes.

Assay Design:

ig-aa101

Related Documents

Instructions for Use IG-AA101 693.91 KB

Material Safety Data Sheet (MSDS) IG-AA101 267.97 KB

Quality Control Certificates

Quality Control Certificate Lot: AA101-105 297.65 KB
Quality Control Certificate Lot: AA101-104 159.33 KB
Quality Control Certificate Lot: AA101-103 160.09 KB
Quality Control Certificate Lot: AA101-102 159.62 KB

Remicade® is a trademark of Janssen Biotech, Inc./Merck & Co.

Remsima® is a trademark of CellTrion Inc.

Back to all Products

The Kit at a glance:

Photo for AA&AB

Required Volume (µL) 10
Incubation Time (min) 105
Sample Serum or Plasma
Package Size 96 Tests
Standard Range (ng/mL, 10x) 0-2000
Detection Limit (ng/mL) 5
Spike Recovery (%) >95
Shelf Life (years) 2

Standard Curve:

ig-aa101